Beam Therapeutics
Price & Volume
Stats
See moreOpen | $19.19 |
Previous Close | $19.71 |
Day Range | $18.95-$19.37 |
52W Range | $13.52-$35.25 |
Market Cap | $1.9B |
Shares Short | 18M |
Financials
See moreRevenue (12 Mos) | $63.5M |
Revenue Growth (YoY) | -90.5% |
Gross Profit (12 Mos) | -$304M |
Diluted EPS | -$4.58 |
News
See moreYahoo Finance • 25 days ago
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
Yahoo Finance • last month
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration
Yahoo Finance • 2 months ago
Beam Therapeutics Announces Pricing of Underwritten Offering
About
CEO | Mr. John M. Evans M.B.A. |
Address | 238 Main Street, Cambridge, MA, United States, 02142 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 483 |
